Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Colistin (Polymyxin E) vs Linaclotide (Linzess)
An educational, source-based comparison of Colistin (Polymyxin E) and Linaclotide (Linzess) — how each peptide works, what it's researched for, and what to know before going deeper.
Last-resort lipopeptide antibiotic for multidrug-resistant Gram-negatives.
Cationic cyclic lipopeptide that disrupts the outer membrane of Gram-negative bacteria by binding lipid A of LPS, causing membrane permeability and cell death.
- Carbapenem-resistant Acinetobacter, Klebsiella, Pseudomonas
- • FDA-approved.
- • Nephrotoxicity and neurotoxicity dose-limiting.
Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.
- IBS-C
- Chronic idiopathic constipation
- Functional constipation in children
- • FDA-approved.
- • Contraindicated in children <2 years; diarrhea common.
Colistin (Polymyxin E) vs Linaclotide (Linzess) — Key differences
- Class: Colistin (Polymyxin E) is classified as Polymyxin · Infectious Disease, while Linaclotide (Linzess) is GC-C Agonist · Gastrointestinal.
- Primary research focus: Colistin (Polymyxin E) — carbapenem-resistant acinetobacter, klebsiella, pseudomonas; Linaclotide (Linzess) — ibs-c.
- Tag: FDA-Approved · Antibiotic vs FDA-Approved · GI.